Ревматоидный артрит: некоторые компоненты гемостаза и воспаление
https://doi.org/10.14412/1996-7012-2019-3-87-94
Аннотация
В обзоре содержатся сведения о физиологии системы гемостаза и ее составляющих, обсуждается связь системы гемостаза с воспалением. Описаны физиология нормального гемостаза, взаимодействие тромбоцитов с эндотелиальными клетками и лейкоцитами, а также с фактором фон Виллебранда и системой комплемента и их роль при ревматоидном артрите.
Об авторах
Ф. А. Чельдиева
Лаборатория сосудистой ревматологии, клинико-диагностическое лабораторное отделение Научно-исследовательского института ревматологии им. В.А. Насоновой
Россия
Россия
115522, Москва, Каширское шоссе, 34А.
Т. М. Решетняк
Лаборатория сосудистой ревматологии, клинико-диагностическое лабораторное отделение Научно-исследовательского института ревматологии им. В.А. Насоновой; кафедра ревматологии Российской медицинской академии непрерывного профессионального образования Минздрава России
Россия
Россия
Решетняк Татьяна Магомедалиевна.
115522, Москва, Каширское шоссе, 34А; 2125993, Москва, ул. Баррикадная, 2/1, стр. 1.
Литература
1. Sira J, Eyre L. Physiology of haemostasis. Anaesthesia & Intensive Care Medicine. 2016; 17(2):79—82. doi:10.1016/j.mpaic.2015.11.004.
2. Hoffman M, Monroe DM. 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001 Jun;85(6):958-65.
3. Решетняк ВИ, Журавель СВ, Кузнецова НК, Писарев ВМ, Клычникова ЕВ, Сюткин ВЕ, Решетняк ТМ. Система гемостаза в норме и при трансплантации печени (обзор). Общая реаниматология. 2018;(5):85-96.
4. Струкова СМ. Основы физиологии гемостаза. 2-е изд. Москва: Издательство МГУ; 2013.
5. Aksu K, Donmez A, Keser G. Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management. Curr Pharm Des. 2012;18(11): 1478-93.
6. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004 Jun 8; 109(22):2698-704. doi: 10.1161/01.CIR.0000131660.51520.9A.
7. Margetic S. Inflammation and haemosta¬sis. Biochem Med (Zagreb). 2012:22(1):49-62. doi: 10.11613/BM.2012.006.
8. Aisina RB, Mukhametova LI, Ostryakova EV, et al. Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thromboses in patients with the antiphospholipid syndrome. Biomed Khim. 2014 Jan-Feb;60(1):72-93. doi: 10.1134/S1990750813010010.
9. Katz OB, Brenner B, Horowitz NA. Thrombosis in vasculitic disorders — clinical manifestations, pathogenesis and management. Thromb Res. 2015 Sep;136(3):504-12. doi: 10.1016/j.thromres.2015.07.016. Epub 2015 Jul 15.
10. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol. 2009 Jun;5(6): 332-40. doi: 10.1038/nrrheum.2009.81.
11. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012 Jun 18;12:41. doi: 10.1186/1471-2377-12-41.
12. Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011 Jan 10;9:1. doi: 10.1186/1741-7015-9-1.
13. Van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis. 2014 Jun;73(6),954-7. doi: 10.1136/annrheumdis-2013-204767. Epub 2014 Jan 15.
14. Thachil J. Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective. Semin Thromb Hemost. 2015 Sep; 41(6):572-581. doi: 10.1055/s-0035-1556589. Epub 2015 Aug 15.
15. Borensztajn KS, von der Thu sen JH, Spek CA. The role of coagulation in chronic inflammatory disorders: A jack of all trades. Curr Pharm Des. 2011;17(1):9-16. doi: 10.2174/138161211795049813.
16. Pottinger BE, Read RC, Paleolog EM, et al. Von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989 Feb; 53(4):387-394. doi: 10.1016/0049-3848(89)90317-4.
17. Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014 Oct;73(10):1774-80. doi: 10.1136/annrheumdis-2013-203380. Epub 2013 Aug 7.
18. Van Doornum S, McColl G, Jenkins A, et al. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum. 2003 Jan;48(1):72-80. doi: 10.1002/art.10735.
19. Bacon PA, Raza K, Banks MJ, et al. The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol. 2002 Jan-Feb;21:1-17. doi: 10.1080/08830180210413.
20. Ha nsel S, La ssig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis. 2003 Sep; 170(1):177-80. doi: 10.1016/S0021-9150(03)00281-8.
21. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010 Jan;30(1):5-9. doi: 10.1055/s-0037-1617146.
22. Mukubo Y, Kawamata M. Perioperative hypercoagulability in patients with rheumatoid arthritis: Sonoclot study. JAnesth. 2004; 18(1):62-4. doi: 10.1007/s00540-003-0206-4.
23. Peters MJ, Nurmohamed MT, van Eyk I, et al. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis. 2009 Jul;68(7):1232-3. doi: 10.1136/ard.2008.097485.
24. Cunningham M, Marks N, Barnado A, et al. Are Microparticles the Missing Link between Thrombosis and Autoimmune Diseases? Involvement in Selected Rheumatologic Diseases. Semin Thromb Hemost 2014 Sep;40(6):675-81. doi: 10.1055/s-0034-1387924. Epub 2014 Aug 31.
25. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009 Mar;101(3):439-51. doi: 10.1160/TH08-08-0521.
26. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999 Apr;30(2):111-42. doi: 10.1016/S1040-8428(98)00044-4.
27. Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood. 2009 Jan 29;113(5):1112-21. doi: 10.1182/blood-2008-06-163832. Epub 2008 Sep 18.
28. Knijff-Dutmer EA, Koerts J, Nieuwland R, et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum. 2002 Jun;46(6):1498-503. doi: 10.1002/art.10312.
29. Van Eijk IC, Tushuizen ME, Sturk A, et al. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7): 1378-82. doi: 10.1136/ard.2009.118372. Epub 2009 Nov 16.
30. Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008 Sep 1; 205(9):2065-74. doi: 10.1084/jem.20080130. Epub 2008 Aug 11.
31. Holers VM, Banda NK. Complement in the Initiation and Evolution of Rheumatoid Arthritis. Front Immunol. 2018 May 28;9:1057. doi: 10.3389/fimmu.2018.01057. eCollection 2018.
32. Trouw LA, Pickering MC. Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017 Sep;13(9):538-547. doi: 10.1038/nrrheum.2017.125. Epub 2017 Aug 10.
33. Wiegner R, Chakraborty S, Huber-Lang M. Complement-coagulation crosstalk on cellular and artificial surfaces. Immunobiology. 2016 Oct;221;(10):1073-9. doi: 10.1016/j.imbio.2016.06.005. Epub 2016 Jun 19.
34. Foley JH. Examining coagulation-com-plement crosstalk: complement activation and thrombosis. Thromb Res. 2016 May;141 Suppl 2:S50-4. doi: 10.1016/S0049-3848(16)30365-6.
35. Wiedmer T, Esmon CT, Sims PJ. On the Mechanism by Which Complement Proteins C5b-9 Increase Platelet Prothrombinase Activity. JBiol Chem. 1986 Nov 5;261(31): 14587-92.
36. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006 Oct 1; 177(7):4794-802. doi: 10.4049/jimmunol.177.7.4794.
37. Langer F, Spath B, Fischer C, et al. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood. 2013 Mar 21;121(12):2324-35. doi: 10.1182/blood-2012-10-460493. Epub 2013 Jan 11.
38. Egge KH, Thorgersen EB, Pischke SE, et al. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. Immunobiology. 2015 August;220(8):999-1005. doi: 10.1016/j.imbio.2015.04.002. Epub 2015 Apr 27.
39. Landsem A, Fure H, Christiansen D, et al. The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. Clin Exp Immunol. 2015 Oct;182(1):81-9. doi: 10.1111/cei.12663. Epub 2015 Aug 2.
40. Ovstebo R, Hellum M, Aass HC, et al. Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria meningitidis-exposed whole blood. Innate Immun. 2014 Jul;20(5): 552-60. doi: 10.1177/1753425913502099. Epub 2013 Sep 19.
41. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989 May 25;264(15):9053-60.
42. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996 Mar; 7(2):157-61. doi: 10.1097/00001721-199603000-00011.
43. Boos CJ, Lip GY. Assessment of mean platelet volume in coronary artery disease-what does it mean? Thromb Res. 2007;120(1): 11-13. doi: 10.1016/j.thromres.2006.09.002. Epub 2006 Oct 12.
44. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets. 2000 Feb;11(1):28-32. doi: 10.1080/09537100075760.
45. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009 Jan;101(1):151-6. doi: 10.1160/TH08-03-0186.
46. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, et al. Platelet function in rheumatoid arthritis: arthritic and cardiovas-cular implications. Rheumatology International. 2011 Feb;31(2):153-64. doi: 10.1007/s00296-010-1446-x.
47. Muscari A, De Pascalis S, Cenni A, et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost. 2008 Jun;99(6):1079-84. doi: 10.1160/TH07-12-0712.
48. Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: Cause or consequence? Int Immunopharmacol. 2015 Sep;28(1):655-65. doi: 10.1016/j.intimp.2015.07.044. Epub 2015 Aug 4.
49. Long AT, Kenne E, Jung R, et al. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2016 Mar;14(3):427-37. doi: 10.1111/jth.13235. Epub 2016 Feb 9.
50. Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. FrontPediatr. 2018 May 23;6:142. doi: 10.3389/fped.2018.00142. eCollection 2018.
51. Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardio-vascular events. Semin Thromb Hemost. 2010 Jul;36(4):452-7. doi: 10.1055/s-0030-1254054. Epub 2010 Jul 7.
52. Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012 Jan;64(1): 53-61. doi: 10.1002/art.33322.
53. Matta F, Singala R, Yaekoub AY, et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009 Jan; 101(1):134-8. doi: 10.1160/TH08-08-0551.
54. Kang JH, Keller JJ, Lin YK, Lin HC. A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. J Vasc Surg. 2012 Dec; 56(6):1642-8. doi: 10.1016/j.jvs.2012.05.087. Epub 2012 Oct 22.
55. Page C, Pitchford S. Platelets and allergic inflammation. Clin Exp Allergy. 2014 Jul;44(7): 901-913. doi: 10.1111/cea.12322.
56. Edwards CJ, Arden NK, Fisher D, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford). 2005 Nov;44(11):1394-8. doi: 10.1093/rheumatology/kei024. Epub 2005 Jul 19.
57. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010 Feb;49(2):295-307. doi: 10.1093/rheumatology/kep366. Epub 2009 Nov 27.
58. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and metaanalysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011 Nov 1;108(9):1362-70. doi: 10.1016/j.amj-card.2011.06.054. Epub 2011 Aug 17.
59. Macias I, Garcia-Perez S, Ruiz-Tudela M, et al. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol. 2005 Nov;32(11):2102-8.
60. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of car-diovascular disease. Circulation. 2001 Apr 3; 103(13):1813-8. doi: 10.1161/01.CIR.103.13.1813.
61. Zoller B, Li X, Sundquist J, et al. Risk of venous thromboembolism in first- and second-generation immigrants in Sweden. Eur J Intern Med. 2012 Jan;23(1):40-7. doi: 10.1016/j.ejim.2011.07.015. Epub 2011 Aug 23.
62. Kim SC, Solomon DH, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17. doi: 10.1016/j.amjmed.2014.11.025. Epub 2014 Dec 20.
63. Сатыбалдыева МА. Ревматоидный артрит и венозные тромбоэмболические осложнения. Научно-практическая ревматология. 2016;54(4):456-62. doi: 10.14412/1995-4484-2016-456-462.
Рецензия
Просмотров: 814
Послать статью по эл. почте 